Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

gram, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a CRL from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011.  In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting.  In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.  In May 2012, Alexza received a second CRL outlining manufacturing deficiencies.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement
This news release and the planned conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certai
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... release its second quarter and year-to-date 2014 financial results ... the U.S. financial markets. The earnings press release will ... Company,s website, www.anipharmaceuticals.com . Arthur ... Charlotte C. Arnold , Vice President and Chief ...
(Date:7/28/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... Nov. 12 Based on its recent analysis ... & Sullivan presents Fovia, Inc. with the 2009 ... Innovation of the Year. Fovia is being recognized ... platform that offers unrivaled image quality and uncompromised ...
... Corporation (Nasdaq: THOR ), a world leader in ... restore failing hearts, said today that it will webcast ... II Destination Therapy clinical trial that will be presented ... American Heart Association(AHA) Scientific Sessions 2009. , The event ...
Cached Medicine Technology:Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 2Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 3Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 4
(Date:7/28/2014)... Mitul R. Patel, DDS and concerned ... MGE Management Experts Benefit Dinner May 30, in St. ... Dentists to raise funds for the Improving Youth Literacy ... and Youth Programs across America. The funds raised are ... and audio books to directly tackle illiteracy and help ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release ... The new book, DOC X MD Funny Feelings ... telling style with humor and medical accuracy. The book is ... find answers to those age-old questions that most folks are ... Why do mosquitoes bite some and not others? Why do ...
(Date:7/27/2014)... the leader in compression technology and sports medicine, has expanded ... The wrist support features an adjustable velcro strap and provides ... more commonly referred to as tennis elbow and golfers elbow, ... tendons attached to the outside of the elbow. Although this ... the wrist and fingers turn into a tendon that attaches ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... of hepatitis E virus (HEV) transmission by blood components ... have HEV in their plasma. The findings, published in ... blood components (eg, red cells, platelets, and fresh frozen ... England. , The study retrospectively screened 225 000 ... Oct, 2012 and Sept, 2013 for HEV RNA. 79 ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Roughly 15% of children suffer from migraines, and approximately one-third ... of symptoms that can include weakness, blind spots, and even ... new study soon to be published in The Journal ... children and a heart defect called patent foramen ovale, which ...
... cells in the intestine, which when they mutate can lead ... to combat the effects of those same cancers, the UK ... today. Professor Nick Barker of the Institute of Medical ... identified that the stem cells which are crucial to maintaining ...
... Commons, an initiative of CollabRx, a provider of ... research, announces the publication of a molecular disease ... into molecular subtypes, rather than traditional histological or ... subtype, including specific assays, drugs, and clinical trials. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, March ... U.S. Food and Drug Administration (FDA) is meeting Wednesday and ... used food dyes and attention-deficit/hyperactivity disorder (ADHD), and if so, ... industry against some parents, public watchdog groups and academics who,ve ...
... HealthDay Reporter , WEDNESDAY, March 30 (HealthDay News) -- ... nursing homes, a new study shows. Researchers say the ... lead to improvements in patient care. Nor does it appear ... in terms of fewer lawsuits. "Nursing homes that are ...
... for Maternal-Fetal Medicine (SMFM) weighed in on today,s FDA ... caproate, also known as 17P. This FDA announcement ... and others regarding the costs of the just-released pharmaceutical ... made by KV Pharmaceuticals, is being sold at $1,500 ...
Cached Medicine News:Health News:Attacking bowel cancer on 2 fronts 2Health News:Researchers publish molecular disease model for melanoma 2Health News:Researchers publish molecular disease model for melanoma 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 2Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 4Health News:Lawsuits Aren't Improving Nursing Home Care: Study 2Health News:Lawsuits Aren't Improving Nursing Home Care: Study 3Health News:Lawsuits Aren't Improving Nursing Home Care: Study 4Health News:Society for Maternal-Fetal Medicine commends FDA on makena announcement 2
Inquire...
... MicroAire Power Assisted Lipoplasty Device uses a 2-mm ... facilitate the movement of the cannula in tissue. ... with more fibrous tissue. That makes the lipoplasty ... will ease your mind to learn that the ...
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
... new term being used today to describe the nature ... that may have been used in silicone implants in ... is not new technology cohesive is simply a ... together nature of the gel. All of Mentor silicone ...
Medicine Products: